Abstract: The present disclosure relates to pharmaceutical composition comprising 1) an amorphous solid dispersion comprising pralsetinib, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable hydrophilic polymer; and 2) an effervescent couple; and crystalline forms of pralsetinib and pralsetinib hydrochloride salt, which are useful as a RET selective inhibitors. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.

Abstract: Disclosed herein are drug delivery devices and their use as a means of achieving controlled release of one or more active pharmaceutical ingredients. In particular, disclosed herein is an implantable drug delivery device comprising an inner core comprising one or more active pharmaceutical ingredients distributed throughout a first water-insoluble polymer; an intermediate coating positioned around the inner core, said intermediate coating comprising an acrylate polymer; and an outer coating positioned around the intermediate coating, said outer coating comprising a second water-insoluble polymer; wherein the acrylate polymer is formed from one or more monomers of formula (I).